HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Myeloma News

Breaking Headlines

Aug. 11, 2022

Cancer Buddies and Coaching

Aug. 11, 2022

Journaling Your Myeloma Story Can Improve Your Health

Aug. 11, 2022

Myeloma Round Table: Essential Information for Newly Diagnosed Patients — Chicago (Part 1)

Aug. 09, 2022

FDA Grants Breakthrough Therapy Designation to Talquetamab for Multiple Myeloma

Aug. 09, 2022

Building Your HealthCare Team

Aug. 09, 2022

HealthTree Foundation Launches New Journaling Feature for Multiple Myeloma Patients

Aug. 08, 2022

Myeloma Round Table: Treating Relapsed/Refractory Disease at MD Anderson — Houston (Part 2)

Aug. 08, 2022

Comparing Black vs. White Myeloma Patient Outcomes

Aug. 07, 2022

Join Us In Person or Online for the Buffalo Myeloma Round Table on September 17

Aug. 04, 2022

Myeloma Round Table: Precursors Through First Treatment — Houston (Part 1)

Aug. 04, 2022

Balance Part 2: Where to Start and How to Improve

Aug. 03, 2022

Creating a Myeloma Community through Movement

Recent Articles

Full Show: Mid-Year Myeloma Update with Paul Richardson, MD, Dana Farber Cancer Institute image
Full Show: Mid-Year Myeloma Update with Paul Richardson, MD, Dana Farber Cancer Institute

August 2, 2022
An Additional Update for Oncopeptides’ Pepaxto (Melflufen) image
An Additional Update for Oncopeptides’ Pepaxto (Melflufen)

July 28, 2022
Myeloma Round Table: Addressing Myeloma Disparities image
Myeloma Round Table: Addressing Myeloma Disparities

July 28, 2022
Gaps in Optimized Genetic and Imaging Testing for Myeloma Patients image
Gaps in Optimized Genetic and Imaging Testing for Myeloma Patients

July 26, 2022
European Medicines Agency Beats FDA to the Punch with Conditional Approval of Teclistamab for Multiple Myeloma image
European Medicines Agency Beats FDA to the Punch with Conditional Approval of Teclistamab for Multiple Myeloma

July 26, 2022

New in Myeloma

FDA Grants Breakthrough Therapy Designation to Talquetamab for Multiple Myeloma image
FDA Grants Breakthrough Therapy Designation to Talquetamab for Multiple Myeloma
An Additional Update for Oncopeptides’ Pepaxto (Melflufen) image
An Additional Update for Oncopeptides’ Pepaxto (Melflufen)
European Medicines Agency Beats FDA to the Punch with Conditional Approval of Teclistamab for Multiple Myeloma image
European Medicines Agency Beats FDA to the Punch with Conditional Approval of Teclistamab for Multiple Myeloma
Who Responds Best to the Multiple Myeloma BCMA Bispecific Antibodies? image
Who Responds Best to the Multiple Myeloma BCMA Bispecific Antibodies?
Three Genes That Indicate a Potential Response to Selinexor Myeloma Therapy image
Three Genes That Indicate a Potential Response to Selinexor Myeloma Therapy
A New Revision to the Revised Myeloma Staging System? image
A New Revision to the Revised Myeloma Staging System?
Load More

Life With Myeloma

Cancer Buddies and Coaching image
Cancer Buddies and Coaching
Journaling Your Myeloma Story Can Improve Your Health image
Journaling Your Myeloma Story Can Improve Your Health
Comparing Black vs. White Myeloma Patient Outcomes image
Comparing Black vs. White Myeloma Patient Outcomes
Balance Part 2: Where to Start and How to Improve image
Balance Part 2: Where to Start and How to Improve
Creating a Myeloma Community through Movement image
Creating a Myeloma Community through Movement
Myeloma Story of a CAR-T Cell Therapy image
Myeloma Story of a CAR-T Cell Therapy
Load More

Myeloma Basics

Building Your HealthCare Team image
Building Your HealthCare Team
How Long Will CAR-T Cell Therapy Last? image
How Long Will CAR-T Cell Therapy Last?
How Do CAR-T Cells Kill Myeloma? image
How Do CAR-T Cells Kill Myeloma?
The Difference Between 1Q Gain and 1Q Amplification in Multiple Myeloma image
The Difference Between 1Q Gain and 1Q Amplification in Multiple Myeloma
What are CAR-T Cells? image
What are CAR-T Cells?
All About CARVYKTI for Multiple Myeloma image
All About CARVYKTI for Multiple Myeloma
Load More

HealthTree

Myeloma Round Table: Essential Information for Newly Diagnosed Patients — Chicago (Part 1) image
Myeloma Round Table: Essential Information for Newly Diagnosed Patients — Chicago (Part 1)
Myeloma Round Table: Treating Relapsed/Refractory Disease at MD Anderson — Houston (Part 2) image
Myeloma Round Table: Treating Relapsed/Refractory Disease at MD Anderson — Houston (Part 2)
Myeloma Round Table: Precursors Through First Treatment — Houston (Part 1) image
Myeloma Round Table: Precursors Through First Treatment — Houston (Part 1)
Full Show: Mid-Year Myeloma Update with Paul Richardson, MD, Dana Farber Cancer Institute image
Full Show: Mid-Year Myeloma Update with Paul Richardson, MD, Dana Farber Cancer Institute
Myeloma Round Table: Addressing Myeloma Disparities image
Myeloma Round Table: Addressing Myeloma Disparities
Myeloma Round Table: Studies from the American Society of Hematology Meeting (ASH 2021) image
Myeloma Round Table: Studies from the American Society of Hematology Meeting (ASH 2021)
Load More

Clinical Trials

The FDA Expanded Access Program for Multiple Myeloma and Early Access for Teclistamab image
The FDA Expanded Access Program for Multiple Myeloma and Early Access for Teclistamab
Clinical Trial: Can Yoga Help Alleviate Peripheral Neuropathy After Chemo? image
Clinical Trial: Can Yoga Help Alleviate Peripheral Neuropathy After Chemo?
ASH 2021: Key Trial Confirms Impact of Daratumumab image
ASH 2021: Key Trial Confirms Impact of Daratumumab
Clinical Trial: A New Myeloma Therapy Tasquinimod Targeting MDSCs image
Clinical Trial: A New Myeloma Therapy Tasquinimod Targeting MDSCs
Clinical Trial: A Personalized Vaccine in Smoldering Myeloma at MD Anderson Cancer Center image
Clinical Trial: A Personalized Vaccine in Smoldering Myeloma at MD Anderson Cancer Center
Clinical Trials: Venetoclax for Multiple Myeloma 11;14 Translocation Patients image
Clinical Trials: Venetoclax for Multiple Myeloma 11;14 Translocation Patients
Load More

Research

Gaps in Optimized Genetic and Imaging Testing for Myeloma Patients image
Gaps in Optimized Genetic and Imaging Testing for Myeloma Patients
The Dawning Era of Bispecific Antibodies in Myeloma image
The Dawning Era of Bispecific Antibodies in Myeloma
Watching Your Free Light Chain Ratio to Determine Smoldering Myeloma Progression to Active Myeloma image
Watching Your Free Light Chain Ratio to Determine Smoldering Myeloma Progression to Active Myeloma
A Meeting of the Myeloma Minds in Vienna image
A Meeting of the Myeloma Minds in Vienna
Myeloma-Related Distress During COVID image
Myeloma-Related Distress During COVID
Real-World Data on CAR T-Cell Therapy in Multiple Myeloma image
Real-World Data on CAR T-Cell Therapy in Multiple Myeloma
Load More

HealthTree Press

HealthTree Foundation Launches New Journaling Feature for Multiple Myeloma Patients image
HealthTree Foundation Launches New Journaling Feature for Multiple Myeloma Patients
Myeloma Crowd Changes Its Name to HealthTree Foundation for Multiple Myeloma image
Myeloma Crowd Changes Its Name to HealthTree Foundation for Multiple Myeloma
Cure Today: Teaching Others Through Cancer Advocacy image
Cure Today: Teaching Others Through Cancer Advocacy
Cancer Today: Crowdsourcing Support image
Cancer Today: Crowdsourcing Support
HealthTree Foundation for Multiple Myeloma Wins GSK's First Target the Future Think Tank Challenge image
HealthTree Foundation for Multiple Myeloma Wins GSK's First Target the Future Think Tank Challenge
HealthTree Coach in the News image
HealthTree Coach in the News
Load More

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Legend Biotechnologies
Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811